Cited by

• A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis.

  Shannon NB, Tan JW, Tan HL, Wang W, Chen Y, Lim HJ, Tan QX, Hendrikson J, Ng WH, Loo LY, Skanthakumar T, Wasudevan SD, Kon OL, Lim TKH, Tan GHC, Chia CS, Soo KC, Ong CJ, Teo MCC. Shannon NB, et al. Sci Rep. 2019 Jul 22;9(1):10572. doi: 10.1038/s41598-019-46819-z. Sci Rep. 2019. PMID: 31332257 Free PMC article.
• Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.

  Acs M, Leebmann H, Häusler S, Harter P, Piso P. Acs M, et al. In Vivo. 2022 Jan-Feb;36(1):341-349. doi: 10.21873/invivo.12708. In Vivo. 2022. PMID: 34972732 Free PMC article.
• The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.

  Zhang G, Zhu Y, Liu C, Chao G, Cui R, Zhang Z. Zhang G, et al. J Ovarian Res. 2019 Apr 17;12(1):33. doi: 10.1186/s13048-019-0509-1. J Ovarian Res. 2019. PMID: 30995948 Free PMC article. Review.
• Second-look Surgery for Appendiceal High Grade and Colorectal Cancers Following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

  Breakeit M, Liu D, Cheng A, Suh H, Barat S, Matar A, Alzahrani N, Morris DL. Breakeit M, et al. In Vivo. 2022 Sep-Oct;36(5):2350-2356. doi: 10.21873/invivo.12966. In Vivo. 2022. PMID: 36099142 Free PMC article.
• Primary and metastatic peritoneal surface malignancies.

  Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Cortés-Guiral D, et al. Nat Rev Dis Primers. 2021 Dec 16;7(1):91. doi: 10.1038/s41572-021-00326-6. Nat Rev Dis Primers. 2021. PMID: 34916522 Review.